Literature DB >> 25552708

The Z proteins of pathogenic but not nonpathogenic arenaviruses inhibit RIG-I-like receptor-dependent interferon production.

Junji Xing1, Hinh Ly1, Yuying Liang2.   

Abstract

UNLABELLED: Arenavirus pathogens cause a wide spectrum of diseases in humans ranging from central nervous system disease to lethal hemorrhagic fevers with few treatment options. The reason why some arenaviruses can cause severe human diseases while others cannot is unknown. We find that the Z proteins of all known pathogenic arenaviruses, lymphocytic choriomeningitis virus (LCMV) and Lassa, Junin, Machupo, Sabia, Guanarito, Chapare, Dandenong, and Lujo viruses, can inhibit retinoic acid-inducible gene 1 (RIG-i) and Melanoma Differentiation-Associated protein 5 (MDA5), in sharp contrast to those of 14 other nonpathogenic arenaviruses. Inhibition of the RIG-i-like receptors (RLRs) by pathogenic Z proteins is mediated by the protein-protein interactions of Z and RLRs, which lead to the disruption of the interactions between RLRs and mitochondrial antiviral signaling (MAVS). The Z-RLR interactive interfaces are located within the N-terminal domain (NTD) of the Z protein and the N-terminal CARD domains of RLRs. Swapping of the LCMV Z NTD into the nonpathogenic Pichinde virus (PICV) genome does not affect virus growth in Vero cells but significantly inhibits the type I interferon (IFN) responses and increases viral replication in human primary macrophages. In summary, our results show for the first time an innate immune-system-suppressive mechanism shared by the diverse pathogenic arenaviruses and thus shed important light on the pathogenic mechanism of human arenavirus pathogens. IMPORTANCE: We show that all known human-pathogenic arenaviruses share an innate immune suppression mechanism that is based on viral Z protein-mediated RLR inhibition. Our report offers important insights into the potential mechanism of arenavirus pathogenesis, provides a convenient way to evaluate the pathogenic potential of known and/or emerging arenaviruses, and reveals a novel target for the development of broad-spectrum therapies to treat this group of diverse pathogens. More broadly, our report provides a better understanding of the mechanisms of viral immune suppression and host-pathogen interactions.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25552708      PMCID: PMC4325705          DOI: 10.1128/JVI.03349-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Genome comparison of virulent and avirulent strains of the Pichinde arenavirus.

Authors:  Shuiyun Lan; Lisa McLay; Judy Aronson; Hinh Ly; Yuying Liang
Journal:  Arch Virol       Date:  2008-05-28       Impact factor: 2.574

2.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

3.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

Review 4.  MDA5/RIG-I and virus recognition.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Curr Opin Immunol       Date:  2008-02-12       Impact factor: 7.486

Review 5.  Innate immunity to virus infection.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

Review 6.  Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.

Authors:  Lisa McLay; Aftab Ansari; Yuying Liang; Hinh Ly
Journal:  Antiviral Res       Date:  2012-12-20       Impact factor: 5.970

Review 7.  Junín virus pathogenesis and virus replication.

Authors:  Ashley Grant; Alexey Seregin; Cheng Huang; Olga Kolokoltsova; Allan Brasier; Clarence Peters; Slobodan Paessler
Journal:  Viruses       Date:  2012-10-19       Impact factor: 5.048

Review 8.  Arenavirus variations due to host-specific adaptation.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Viruses       Date:  2013-01-17       Impact factor: 5.048

Review 9.  Multifunctional nature of the arenavirus RING finger protein Z.

Authors:  Sarah Katharina Fehling; Frank Lennartz; Thomas Strecker
Journal:  Viruses       Date:  2012-11-09       Impact factor: 5.048

Review 10.  Treatment of Argentine hemorrhagic fever.

Authors:  Delia A Enria; Ana M Briggiler; Zaida Sánchez
Journal:  Antiviral Res       Date:  2007-11-20       Impact factor: 5.970

View more
  62 in total

1.  Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z.

Authors:  Kathryn M Hastie; Michelle Zandonatti; Tong Liu; Sheng Li; Virgil L Woods; Erica Ollmann Saphire
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  A Proteomics Survey of Junín Virus Interactions with Human Proteins Reveals Host Factors Required for Arenavirus Replication.

Authors:  Christopher M Ziegler; Philip Eisenhauer; Jamie A Kelly; Loan N Dang; Vedran Beganovic; Emily A Bruce; Benjamin R King; David J Shirley; Marion E Weir; Bryan A Ballif; Jason Botten
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

3.  Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.

Authors:  Masaharu Iwasaki; Cherie T Ng; Beatrice Cubitt; Juan C de la Torre
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

4.  Resistance of human plasmacytoid dendritic CAL-1 cells to infection with lymphocytic choriomeningitis virus (LCMV) is caused by restricted virus cell entry, which is overcome by contact of CAL-1 cells with LCMV-infected cells.

Authors:  Masaharu Iwasaki; Siddhartha M Sharma; Brett S Marro; Juan C de la Torre
Journal:  Virology       Date:  2017-08-24       Impact factor: 3.616

5.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Authors:  Xavier Carnec; Mathieu Mateo; Audrey Page; Stéphanie Reynard; Jimmy Hortion; Caroline Picard; Elsie Yekwa; Laura Barrot; Stéphane Barron; Audrey Vallve; Hervé Raoul; Caroline Carbonnelle; François Ferron; Sylvain Baize
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

6.  Highly Pathogenic New World and Old World Human Arenaviruses Induce Distinct Interferon Responses in Human Cells.

Authors:  Cheng Huang; Olga A Kolokoltsova; Nadezhda E Yun; Alexey V Seregin; Shannon Ronca; Takaaki Koma; Slobodan Paessler
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

7.  Human Plasmacytoid Dendritic Cells Elicited Different Responses after Infection with Pathogenic and Nonpathogenic Junin Virus Strains.

Authors:  Soledad Negrotto; Hebe A Mena; Agustin E Ure; Carolina Jaquenod De Giusti; Mariela Bollati-Fogolín; Elba M Vermeulen; Mirta Schattner; Ricardo M Gómez
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

8.  Axl Can Serve as Entry Factor for Lassa Virus Depending on the Functional Glycosylation of Dystroglycan.

Authors:  Chiara Fedeli; Giulia Torriani; Clara Galan-Navarro; Marie-Laurence Moraz; Hector Moreno; Gisa Gerold; Stefan Kunz
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

9.  Activation of the RLR/MAVS Signaling Pathway by the L Protein of Mopeia Virus.

Authors:  Lei-Ke Zhang; Qi-Lin Xin; Sheng-Lin Zhu; Wei-Wei Wan; Wei Wang; Gengfu Xiao
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

10.  TRIM29 Negatively Regulates the Type I IFN Production in Response to RNA Virus.

Authors:  Junji Xing; Ao Zhang; Laurie J Minze; Xian Chang Li; Zhiqiang Zhang
Journal:  J Immunol       Date:  2018-05-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.